Santpal Mavi, MD
Pulmonary Disease · Gallipolis, OHNPI 1770534497
Payments from drug & device makers
Across 283 payments — averaging $17.14 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$806
- ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$471
- Amgen$455
- Boehringer Ingelheim$343
- Mylan Specialty L.p.$280
- Sanofi$263
- plus $2K from 29 others
What the payments were for
- Food & beverage$4,75098%
- Education$1002%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca(2 entities) | 43 | $806 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 30 | $471 |
| Amgen | 28 | $455 |
| Boehringer Ingelheim | 20 | $343 |
| Mylan Specialty L.p. | 17 | $280 |
| Sanofi | 13 | $263 |
| Viatris Specialty LLC | 12 | $246 |
| GSK | 20 | $243 |
| Johnson & Johnson | 13 | $205 |
| Takeda Pharmaceuticals U.S.A., Inc. | 10 | $202 |
| Regeneron Healthcare Solutions, Inc. | 9 | $158 |
| Verona Pharma, Inc. | 6 | $153 |
| Baxter Healthcare | 8 | $144 |
| Genentech USA, Inc. | 12 | $132 |
| Merck | 7 | $118 |
| Novo Nordisk | 5 | $91 |
| Insmed, Inc. | 3 | $86 |
| Philips North America LLC | 4 | $73 |
| Novartis | 3 | $46 |
| Lilly USA, LLC | 1 | $45 |
| E.r. Squibb & Sons, L.L.C. | 2 | $31 |
| Pfizer | 2 | $29 |
| Jazz Pharmaceuticals Inc. | 2 | $27 |
| Circassia Inc. | 2 | $25 |
| Bayer | 1 | $22 |
| Abiomed | 1 | $21 |
| Grifols USA, LLC | 1 | $18 |
| Electromed, Inc. | 1 | $18 |
| Inspire Medical Systems, Inc. | 1 | $17 |
| Pulmonx Corporation | 1 | $17 |
| Teva Pharmaceuticals USA, Inc. | 1 | $15 |
| Apria Healthcare LLC | 1 | $12 |
| Advanced Respiratory, Inc | 1 | $12 |
| Medtronic | 1 | $12 |
| Shire North American Group Inc | 1 | $11 |
How this compares
$4,850 in reported general payments places this provider in the 60th percentile of 571 pulmonary disease providers in Ohio.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 459 | $347,816 |
| Spiriva RespimatTiotropium Bromide | 304 | $198,990 |
| Breo ElliptaFluticasone/Vilanterol | 228 | $114,751 |
| Spiriva HandihalerTiotropium Bromide | 160 | $109,871 |
| SymbicortBudesonide/Formoterol Fumarate | 187 | $66,208 |
| Advair HfaFluticasone Propion/Salmeterol | 137 | $51,839 |
| Incruse ElliptaUmeclidinium Bromide | 97 | $42,796 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 57 | $31,127 |
| Combivent RespimatIpratropium/Albuterol Sulfate | 34 | $30,545 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 49 | $26,320 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 1,004 | $24,392 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 168 | $22,316 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 17 | $18,127 |
| DuleraMometasone/Formoterol | 42 | $16,377 |
| Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate | 118 | $14,904 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Breo Ellipta, Incruse Ellipta, Anoro Ellipta, Arnuity Ellipta | $243 | $544,711871 claims |
| Boehringer IngelheimSpiriva Respimat, Combivent Respimat, Stiolto Respimat | $343 | $255,854387 claims |
| AstraZenecaSymbicort, Breztri Aerosphere | $806 | $84,335204 claims |
| MerckDulera | $118 | $16,37742 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 571 pulmonary disease providers in Ohio.
Other pulmonary disease in Gallipolis
- Bruce CorserCincinnati$8.2M
- Edward CordascoColumbus$8M
- Kristin HighlandCleveland$3.2M
- Brian ZenoColumbus$2.9M
- Jean ElwingCincinnati$2.4M
- Roy St JohnColumbus$1.9M
- Nishant GuptaCincinnati$1.5M
- Robert BaughmanCincinnati$1.1M
- Francis McCormackCincinnati$1.1M
- Leslie TolleCleveland$1M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.